The results of the phase 3 trial (KEYNOTE-189) evaluating pembrolizumab in combination with chemotherapy in frontline setting in nonsquamous NSCLC patients without sensitizing EGFR or ALK mutations have been recently reported. Here, EGFR is linked to non-small cell lung carcinoma.